Literature DB >> 11546952

Time to discontinuation of the first highly active antiretroviral therapy regimen: a comparison between protease inhibitor- and non-nucleoside reverse transcriptase inhibitor-containing regimens.

M Dorrucci1, P Pezzotti, B Grisorio, C Minardi, M S Muro, V Vullo, A Monforte.   

Abstract

Data from a cohort of HIV-positive individuals who were antiretroviral naive at enrollment were analysed to estimate the probability of discontinuing the first highly active antiretroviral therapy (HAART) regimen, comparing protease inhibitor- and non-nucleoside reverse transcriptase-containing regimens. Of the 2002 individuals who began HAART, 857 (42.8%) discontinued their first regimen. No statistically significant difference was found in the time to discontinuation by specific type of regimen, either when considered overall or by specific reason.

Mesh:

Substances:

Year:  2001        PMID: 11546952     DOI: 10.1097/00002030-200109070-00020

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  8 in total

Review 1.  Therapeutic drug monitoring: pharmacologic considerations for antiretroviral drugs.

Authors:  Jennifer J Kiser; Peter L Anderson; John G Gerber
Journal:  Curr HIV/AIDS Rep       Date:  2005-06       Impact factor: 5.071

2.  Rates and reasons for early change of first HAART in HIV-1-infected patients in 7 sites throughout the Caribbean and Latin America.

Authors:  Carina Cesar; Bryan E Shepherd; Alejandro J Krolewiecki; Valeria I Fink; Mauro Schechter; Suely H Tuboi; Marcelo Wolff; Jean W Pape; Paul Leger; Denis Padgett; Juan Sierra Madero; Eduardo Gotuzzo; Omar Sued; Catherine C McGowan; Daniel R Masys; Pedro E Cahn
Journal:  PLoS One       Date:  2010-06-01       Impact factor: 3.240

3.  Evaluating competing adverse and beneficial outcomes using a mixture model.

Authors:  Bryan Lau; Stephen R Cole; Richard D Moore; Stephen J Gange
Journal:  Stat Med       Date:  2008-09-20       Impact factor: 2.373

4.  Short-term discontinuation of HAART regimens more common in vulnerable patient populations.

Authors:  Lindsay S Robison; Andrew O Westfall; Michael J Mugavero; Mirjam C Kempf; Stephen R Cole; Jeroan J Allison; James H Willig; James L Raper; C Mel Wilcox; Michael S Saag
Journal:  AIDS Res Hum Retroviruses       Date:  2008-11       Impact factor: 2.205

5.  Tolerability and efficacy of PI versus NNRTI-based regimens in subjects receiving HAART during acute or early HIV infection.

Authors:  Linda G Apuzzo; Florin Vaida; Joel E Gallant; Karin B Ernstrom; Susan J Little; Jean-Pierre Routy; Ann C Collier; Brian Conway; Martin H Markowitz; Frederick M Hecht; Bruce D Walker; Elizabeth Connick; Joseph B Margolick
Journal:  J Acquir Immune Defic Syndr       Date:  2009-03-01       Impact factor: 3.731

6.  The Reason for Regimen Change Among HIV/AIDS Patients Initiated on First Line Highly Active Antiretroviral Therapy in Southern Ethiopia.

Authors:  Beharu Woldemedhin; Nasir Tajure Wabe
Journal:  N Am J Med Sci       Date:  2012-01

7.  Sex-based differences in antiretroviral therapy initiation, switching and treatment interruptions: global overview from the International Epidemiologic Databases to Evaluate AIDS (IeDEA).

Authors:  Michelle L Giles; Amit C Achhra; Alison G Abraham; Andreas D Haas; Michael John Gill; Man Po Lee; Marco Luque; Catherine McGowan; Morna Cornell; Paula Braitstein; Nathalie de Rekeneire; Renaud Becquet; Kara Wools-Kaloustian; Matthew Law
Journal:  J Int AIDS Soc       Date:  2018-06       Impact factor: 5.396

8.  Incidence rate of modifying or discontinuing first combined antiretroviral therapy regimen due to toxicity during the first year of treatment stratified by age.

Authors:  Thiago Silva Torres; Sandra Wagner Cardoso; Luciane S Velasque; Valdilea G Veloso; Beatriz Grinsztejn
Journal:  Braz J Infect Dis       Date:  2013-09-09       Impact factor: 3.257

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.